IP Library Granted Patent US 7,981,859
Granted Patent B2
US 7,981,859 · App. 10/944,601 · Granted Jul 19, 2011

Glycopeptide composition with improved antibiotic activity

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,981,859
App. No.
10/944,601
Granted
Jul 19, 2011
Kind
B2
Abstract

A glycopeptide composition with improved antibiotic activity is disclosed, along with a method of preparing such a composition and a pharmaceutical composition made therefrom.

Claims (10)

1. A Teicoplanin composition, comprising Teicoplanin components or a salt thereof, wherein the composition comprises %(mg TA3-1)/(mg TA3-1+mg TA2) of 16% to about 73% as measured by HPLC analysis.

2. The composition according to claim 1 , wherein the %(mg TA3-1)/(mg TA3-1+mg TA2) is 17% to about 70%.

3. The composition according to claim 1 , wherein the %(mg TA3-1)/(mg TA3-1+mg TA2) is 18% to about 60%.

4. The composition according to claims 1 , wherein the %(mg TA3-1)/(mg TA3-1+mg TA2) is about 21% to about 55%.

5. The composition according to claim 1 , wherein the %(mg TA3-1)/(mg TA3-1+mg TA2) is about 25% to about 40%.

6. The composition according to claim 1 , wherein TA2 is the total of the Teicoplanin components TA2-1 to TA2-5.

7. The composition according to claim 1 , wherein the composition has a higher antibiotic activity than a corresponding Teicoplanin composition that has a %(mg TA3-1)/(mg TA3-1+TA2) of 6.5%, where the antibiotic activity is measured by a microbiological agar diffusion assay using Staphylococcus aureus ATCC 6538 as test strain and the measured potential potency (IU per mg TA2+TA3-1) is used to calculate the antibiotic activity.

8. The composition according to claim 7 , wherein the potential potency of the Teicoplanin composition is at least 30 IU higher than the corresponding Teicoplanin composition that has a %(mg TA3-1)/(mg TA3-1+TA2) of 6.5%.

9. A pharmiaceutical composition comprising a pharmaceutically acceptable amount of the composition according to claim 1 ; and a pharmaceutically acceptable carrier.

10. A method of treating gram positive bacteria in a patient in need thereof, comprising administering the composition according to claim 9 to a patient.

Assignments (5)
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Nov 1, 2012
From: DEUTSCHE BANK AG, LONDON BRANCH
To: ACTAVIS GROUP HF
Reel/Frame 029229/0470 →
PATENT SECURITY AGREEMENT SUPPLEMENT Recorded Dec 10, 2010
From: ACTAVIS GROUP HF.
To: DEUTSCHE BANK AG, LONDON BRANCH
Reel/Frame 025468/0833 →
CHANGE OF NAME Recorded Sep 27, 2010
From: AXELLIA PHARMACEUTICALS APS
To: XELLIA PHARMACEUTICALS APS
Reel/Frame 025043/0954 →
CHANGE OF NAME Recorded Oct 24, 2008
From: ALPHARMA APS
To: AXELLIA PHARMACEUTICALS APS
Reel/Frame 021735/0030 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2004
From: MATHIESEN, ANITA; KOCH, TORBEN; REIJNS, TIEMEN GEERT PIETER; SUHR-JESSEN, GERD TRINE; THYME, JORN
To: ALPHARMA APS
Reel/Frame 015439/0302 →